Employees: 159
Size Medistim (MEDI.OL) is a Norway Health Care company (Medical Specialties) with a market value of $599M, the 77th largest of 108 Norway companies the cockpit tracks. Shares closed at NOK 319.00 on 18 Nov 2026.
Performance Over six months the shares gained 32.4%, against -20.3% for the median peer and +1.6% for the Norway market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 19.1% over the last twelve months (peer median +14.4%); the operating margin is 28.6% (peer median 7.5%).
Valuation It trades at 31.8× forward earnings against a peer median of 20.0× (5th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 52.3 points above its cost of capital (5.9% WACC).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NOK 796M | NOK 700M | NOK 563M | NOK 521M | NOK 486M |
| Revenue growth | — | +24% | +8% | +7% | — |
| Gross profit | NOK 383M | NOK 321M | NOK 245M | NOK 225M | NOK 218M |
| EBITDA | NOK 255M | NOK 219M | NOK 152M | NOK 150M | NOK 153M |
| Net income | NOK 178M | NOK 159M | NOK 104M | NOK 104M | NOK 114M |
| Free cash flow | n/a | NOK 182M | NOK 137M | NOK 96.8M | NOK 104M |
| Capital expenditure | n/a | NOK 33.0M | NOK 24.7M | NOK 29.7M | NOK 21.1M |
| Total debt | NOK 26.2M | NOK 49.3M | NOK 34.4M | NOK 17.6M | NOK 17.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDI.OL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.3% | -5.5% | 4th highest of 19 |
| 6-month return | +32.4% | -20.3% | 4th highest of 19 |
| Distance from 52-week high | -3.3% | -34.3% | highest of 20 |
| Revenue growth (TTM) | +19.1% | +14.4% | 5th highest of 20 |
| Operating margin | 28.6% | 7.5% | 4th highest of 20 |
| Forward P/E | 31.8× | 20.0× | 5th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | -1.2% | 4.4% | 4th least demanding of 11 |
| Growth delivered (Del g) | +14.5% | +9.3% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -15.6 pp | -7.2 pp | 5th least demanding of 11 |
| ROIC minus cost of capital | +52.3 pp | +0.1 pp | 3rd highest of 19 |
| EV / EBITDA | 22.2× | 13.2× | 3rd most expensive of 8 |
| Net debt / EBITDA | -0.6× | -1.0× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 17.4× | -8.5% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |